No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
VolitionRx Appoints LifeSci Advisors as Investor Relations Consultants
VolitionRX Shares Are Trading Higher After the Company Announced a Study Showed Its Nu.Q Lung Cancer Test Achieved 92% Sensitivity and 89% Positive Predictive Value in Differentiating Malignant From Benign Pulmonary Nodules.
Express News | VolitionRX Announces Pricing of up to $1.9 Million Registered Direct Offering
VolitionRx Announces Pricing of up to $1.9 Million Registered Direct Offering
Benchmark Co. Maintains VolitionRX(VNRX.US) With Hold Rating
VolitionRX (VNRX) Gets a Hold From Benchmark Co.